Abstract
This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone. Patients with Type 2 DM (n=94) were enroled into this randomised, double-blind (sponsor unblinded), placebo-controlled, parallel group trial. Participants received placebo for two weeks before being randomised (2:2:2:2:1:1) to receive doses of GSK256073 5mg twice-daily (BID), 10mg once-daily (QD), 25mg BID, 50mg QD or placebo BID or QD in addition to their current metformin treatment. The primary efficacy endpoint was change from baseline in glycosylated haemoglobin (HbA1c) at week 12. The safety profile of GSK256073 did not significantly differ from that of placebo. Decreases from baseline in HbA1c were observed in all treatment groups but were not statistically significant compared to placebo; at week 12 a maximum decrease of 0.30% from placebo was reached in the GSK256073 50mg QD group. On day 2, GSK256073 significantly decreased non-esterified fatty acid (NEFA) (0-12h) concentrations but pharmacological activity was lost (5mg BID, 10mg QD, 25mg BID) or reduced (50mg QD) at week 6. Drug exposure demonstrated 2-fold ...Continue Reading
References
Oct 1, 1992·Acta Endocrinologica·A A Vaag, H Beck-Nielsen
Jul 1, 1989·The Journal of International Medical Research·M LavezzariF Pamparana
Aug 1, 1988·Diabetes·G M ReavenY D Chen
Jul 1, 1985·Diabetologia·D R MatthewsR C Turner
Mar 1, 1994·The Journal of Clinical Endocrinology and Metabolism·D WormH Beck-Nielsen
Dec 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·C SalorantaM R Taskinen
Nov 1, 1993·Diabetes·C SalorantaL Groop
Oct 1, 1995·Diabetologia·G PaolissoE Ravussin
Sep 10, 1999·Diabetes·A T SantomauroB L Wajchenberg
Jan 5, 2000·European Journal of Clinical Investigation·S E BaldewegS W Coppack
Jul 21, 2000·The Journal of Clinical Investigation·G I Shulman
Jul 25, 2000·Diabetes·M RodenG I Shulman
Jan 5, 2002·Diabetes·J Denis McGarry
Jul 19, 2002·Archives of Internal Medicine·Scott M GrundyUNKNOWN Diabetes Multicenter Research Group
Apr 13, 1963·Lancet·P J RANDLEE A NEWSHOLME
Oct 27, 2005·Diabetes·Mandeep BajajRalph A DeFronzo
Dec 23, 2008·Diabetes Research and Clinical Practice·Viswanathan MohanKeith D Kaufman
Jul 25, 2009·British Journal of Pharmacology·Helen Vosper
Aug 24, 2012·Science Translational Medicine·Brett LauringAndrew Plump
Feb 23, 2013·PLoS Biology·Amandine GirousseDominique Langin
May 25, 2013·Diabetes, Obesity & Metabolism·R L DobbinsA-C Le Monnier de Gouville
Citations
Mar 5, 2016·Current Atherosclerosis Reports·Harsh Goel, Richard L Dunbar
Nov 7, 2015·Biochimie·Pauline MorignyDominique Langin
Jan 15, 2017·Trends in Endocrinology and Metabolism : TEM·Stefan Offermanns
Feb 3, 2018·British Journal of Pharmacology·Kyle W SloopFrancis S Willard
Jul 4, 2019·Clinical Pharmacology in Drug Development·Eric J OlsonJohn J Lepore
Dec 14, 2017·Pharmacological Reviews·Darren M RiddyChristopher J Langmead
Jan 19, 2019·Annals of Clinical and Translational Neurology·Pavan BhargavaPeter A Calabresi
Aug 23, 2017·Annual Review of Nutrition·John C Newman, Eric Verdin
Aug 31, 2019·Nutrients·Amélie I S SobczakAlan J Stewart
Jan 3, 2021·Progress in Lipid Research·Emeline RecazensDominique Langin